Stock listing

NASDAQ:NVCT Nuvectis Pharma, Inc. Stock

Home listing (NASDAQ) of Nuvectis Pharma, Inc.

Follow Nuvectis Pharma, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:NVCT

$19.39 USD -0.90 (-4.4%)

Close on Nov 20, 2026

Past year +229.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$19.02 – $20.18 USDNov 20, 2026
Volume
301,603 sharesNov 20, 2026
Market cap
$666.8M USDAt the close on Nov 20, 2026 · price × 34.39M shares outstanding
52-week range
$5.77 – $29.28 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4.39M USDMedian day 188,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Nuvectis Pharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NVCT · Home$19.39 USD-0.90 (-4.4%)301,603$19.60$20.18$19.02$20.29Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NVCT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$19.39-0.90-4.4%$19.60$20.18$19.02301,603
$20.29+1.09+5.7%$19.26$20.37$18.65189,615
$19.20+0.09+0.5%$19.09$19.92$18.75181,014
$19.11-1.13-5.6%$20.00$20.00$18.64265,409
$20.24+0.010.0%$20.17$20.38$19.60208,983
$20.23-0.77-3.7%$20.82$21.18$20.20206,610
$21.00-0.08-0.4%$21.31$21.78$20.61153,122
$21.08+0.06+0.3%$20.75$21.30$20.23201,680
$21.02+0.11+0.5%$21.09$22.18$19.72385,116
$20.91+3.15+17.7%$18.01$21.05$17.80255,638
$17.76-0.71-3.8%$18.15$18.53$17.24340,097
$18.47-0.87-4.5%$19.08$20.55$17.10373,433
$19.34+0.16+0.8%$19.18$19.69$18.82143,079
$19.18+0.70+3.8%$18.61$19.40$18.10213,587
$18.48-0.09-0.5%$18.46$18.92$18.20168,802
$18.57+0.21+1.1%$18.61$18.97$18.32117,684
$18.36-0.08-0.4%$18.30$18.83$17.91192,736
$18.44-0.05-0.3%$18.56$18.74$18.08144,623
$18.49-1.56-7.8%$20.00$20.41$17.69318,829
$20.05-0.84-4.0%$20.86$20.86$19.83107,900
$20.89+0.19+0.9%$20.55$21.26$20.40110,100
$20.70+0.11+0.5%$20.63$21.72$19.94203,600
$20.59+1.65+8.7%$19.09$20.91$17.85148,800
$18.94+0.34+1.8%$18.81$19.20$18.42198,200
$18.60-0.33-1.7%$18.89$18.89$17.81158,500
$18.93+0.93+5.2%$18.30$19.59$18.30156,900
$18.00-0.15-0.8%$18.27$18.72$17.68184,200
$18.15-1.54-7.8%$19.59$19.88$18.01215,800
$19.69-1.43-6.8%$21.12$21.19$19.55145,800
$21.12+0.99+4.9%$20.11$21.29$19.88153,000
$20.13-0.16-0.8%$20.05$20.42$19.60179,400
$20.29+0.26+1.3%$19.67$20.72$19.67121,100
$20.03-1.36-6.4%$21.54$21.54$19.79188,100
$21.39-0.53-2.4%$22.00$22.24$20.29194,300
$21.92+1.20+5.8%$21.11$22.00$21.04207,500
$20.72-0.40-1.9%$21.33$21.90$20.53168,300
$21.12+0.59+2.9%$20.73$21.62$20.41240,300
$20.53-0.28-1.3%$20.91$21.40$20.11160,000
$20.81+0.59+2.9%$20.00$21.24$19.55137,900
$20.22-1.41-6.5%$21.81$21.95$20.22191,800
$21.63+0.56+2.7%$21.38$21.99$20.65258,200
$21.07-1.93-8.4%$23.00$23.00$20.94169,200
$23.00+1.02+4.6%$22.26$23.18$21.79124,000
$21.98-0.02-0.1%$22.02$22.39$21.40166,400
$22.00+0.62+2.9%$21.27$23.00$21.06880,100
$21.38-0.49-2.2%$22.31$22.31$20.00240,900
$21.87-0.05-0.2%$21.84$22.41$21.31136,400
$21.92-1.43-6.1%$23.00$23.01$21.78166,100
$23.35-0.64-2.7%$23.25$24.12$22.79203,400
$23.99+1.50+6.7%$22.96$24.24$22.28221,100
$22.49-0.29-1.3%$22.09$23.02$22.01107,000
$22.78-1.21-5.0%$23.89$24.54$22.67165,600
$23.99-0.50-2.0%$24.00$24.69$22.73136,300
$24.49+0.12+0.5%$24.00$25.19$23.96117,200
$24.37+0.45+1.9%$24.00$24.62$22.82136,000
$23.92+0.86+3.7%$23.06$24.01$23.06188,500
$23.06+0.33+1.5%$22.80$23.81$22.77176,900
$22.73-1.00-4.2%$23.52$24.35$22.57192,600
$23.73-1.46-5.8%$24.93$25.65$23.29137,200
$25.19+0.19+0.8%$25.03$25.84$24.35319,800
$25.00-0.89-3.4%$25.80$25.80$23.84362,900
$25.89+2.02+8.5%$23.90$25.94$23.85276,625
$23.87+0.31+1.3%$23.56$24.55$23.34231,128
$23.56+0.21+0.9%$23.59$23.93$22.83197,000
$23.35+0.02+0.1%$22.98$23.99$22.36230,000
Ticker
NASDAQ:NVCT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Nuvectis Pharma, Inc. news

Nuvectis Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 95 in all · newest Nov 4, 2026 · oldest 2022
Calls
1 call with a replay · 1 with a transcript · latest Nov 4, 2026
Decks
14 decks · latest Nov 4, 2026

Where Nuvectis Pharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NVCT · Home listing · This pageNASDAQUnited StatesUSD
BOATS:NVCTBOATSUnited StatesUSD

Valuation

Price/book 5.3× against a median of 4.2×: 9th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$526.1M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
5.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.84

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Nuvectis Pharma, Inc. · NASDAQ:NVCTUS$666.8MUS$526.1Mn/an/an/a5.3×n/a0.0×0.84
Attovia Therapeutics, Inc. · NASDAQ:ATTOUS$689.3MUS$297.2Mn/a220×n/a1.7×n/a0.0×n/a
Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRXUS$681.2MUS$549.9Mn/a14.3×n/a4.2×−161.8%0.3×1.15
CARsgen Therapeutics Holdings Ltd. · HKEX:2171US$676.0MUS$477.2Mn/a25.4×n/a4.1×−77.9%0.1×n/a
Philogen SpA · MIL:PHILUS$672.3MUS$532.7M2.7×1.5×n/a1.6×71.8%0.0×n/a
Sun Pharma Advanced Research Co. Ltd. · NSE:SPARCUS$665.9MUS$519.0M3.8×2.5×2.9×4.3×84.7%0.0×n/a
Oscotec Inc. · KRX:039200US$664.8MUS$664.8M11.6×6.3×n/a4.5×54.0%0.0×n/a
Shouyao Holdings Beijing Co. Ltd. Class A · SSE:688197US$647.2MUS$565.0Mn/a37.8×n/a6.8×−18.6%0.0×n/a
Prime Medicine, Inc. · NASDAQ:PRMEUS$645.8MUS$695.1Mn/a98.4×n/a76.5×n/a13.1×2.28
Sagimet Biosciences Inc. - Series A · NASDAQ:SGMTUS$638.7MUS$404.3Mn/an/an/a2.6×n/a0.0×1.96
Gubra A/S · OMXCOP:GUBRAUS$638.5MUS$533.6M2.6×1.4×1.7×4.2×64.1%0.2×n/a
Median of the othersUS$665.4MUS$533.2M3.2×14.3×2.3×4.2×54.0%0.0×1.96

Forecasts

4 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
35.40 USD · Analysts' mean
EPS, year to Dec 2026
-2.03 · 6 analysts

Team and board

Officers

OfficerRole
Ron BentsurChairman, Chief Executive Officer and President
Enrique PoradosuExecutive Vice President, Chief Scientific and Business Officer
Shay ShemeshExecutive Vice President, Chief Development and Operations Officer

Board

DirectorRole
Ron BentsurChairman, Chief Executive Officer and President
James F. OlivieroDirector
Juan SanchezDirector
Ken HobermanDirector
Matthew L. KaplanDirector

Events

Calls

CallWhenStatus
Nuvectis Pharma (NASDAQ:NVCT) Q3 2026 Earnings CallWed, Nov 04, 2026 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open−4.5%
Q2 2026Aug 4, 2026 · Before open−6.9%
Q1 2026May 5, 2026 · Before open+9.2%
Q4 2025Feb 11, 2026 · Before open+0.5%
Q3 2025Nov 4, 2025 · Before open−7.5%
Q2 2025Aug 5, 2025 · Before open−5.3%
Q1 2025May 6, 2025 · Before open−4.4%
Q4 2024Feb 25, 2025−6.8%
Q3 2024Nov 5, 2024 · Before open+17.8%
Q2 2024Aug 6, 2024 · Before open−5.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · After close−10.6%
Q4 2023Mar 5, 2024 · Before open−1.0%
Q3 2023Nov 8, 2023 · Before open−7.8%
Q2 2023Aug 9, 2023 · After close+0.4%
Q1 2023May 10, 2023 · After close+0.8%
Q4 2022Mar 7, 2023 · Before open−4.7%
Q3 2022Nov 8, 2022 · Before open+0.8%
Q2 2022Aug 10, 2022 · After close+2.3%
Q1 2022May 12, 2022 · After close+5.5%
Q4 2021Mar 22, 2022 · Before open+14.4%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings23 slidesNov 4, 2026
Investor Presentation (October 2026)Investor deck24 slidesOctober 2026
Investor Presentation (May 2026)Investor deck27 slidesMay 2026
Investor Presentation (August 2025)Investor deck26 slidesAugust 2025
Investor Presentation (March 2025)Investor deck27 slidesMarch 2025
Investor Presentation (January 2025)Investor deck27 slidesJanuary 2025
Investor Presentation (March 2024)Investor deck25 slidesMarch 2024
Investor Presentation (May 2023)Investor deck24 slidesMay 2023
Investor Presentation (April 2023)Investor deck23 slidesApril 2023
Investor Presentation (March 2023)Investor deck23 slidesMarch 2023
All 14 decks
DeckKindSlidesDate
Investor Presentation (November 2022)Investor deck27 slidesNovember 2022
IPO Roadshow (January 2022)IPO roadshow22 slidesJan 18, 2022
IPO Roadshow (November 2021)IPO roadshow25 slidesNov 4, 2021
IPO Roadshow (November 2021)IPO roadshow24 slidesNov 2, 2021

Open Decks

Financings

RaiseDate
Public offering of shares (follow-on public offering)
Closed: US$115M raised
Use of proceeds: Advance development of NXP100 in PNH and other complement-mediated diseases and the oncology portfolio
Aug 4, 2026
Public offering of common stock
Update: US$100M · US$20 a share · Cantor +6
Dealers: Cantor (lead), H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, Titan Partners, a division of American Capital Partners
Use of proceeds: Advance NXP100, NXP200 and NXP900 programs, hiring, capital expenditures, public company costs and general corporate purposes
Jun 30, 2026
At-the-market programme of shares
Closed: at-the-market programme
Aug 5, 2025
Public offering of common stock
Closed: US$15.5M raised · US$5 a share · Lucid Capital Markets
Dealers: Lucid Capital Markets (lead)
Use of proceeds: Advance NXP800 and NXP900 development, hiring, capital expenditures, public company costs and general corporate purposes
Feb 7, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$5.00 a share on Feb 4, 2022.

Price
US$5.00 a share
Shares offered
3,200,000 shares of common stock
Offering size
US$16 million
Listing
NVCT on the Nasdaq Capital Market
Underwriter
H.C. Wainwright & Co.
Shares delivered
On or about Feb 8, 2022

Steps

StepWhen
Draft sent to the SEC in confidenceJul 30, 2021
Filed publiclyOct 6, 2021
Amended 6 timesNewest Jan 24, 2022
Shares registered with an exchangeFeb 3, 2022
Declared effective by the SECFeb 4, 2022
Final prospectus, with the priceFeb 7, 2022

Open IPO · From the cover of the final prospectus (424B4) filed Feb 7, 2022

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue000149.0K0
Cost of revenue22.9M19.2M12.9M
Gross profit-22.9M-19.1M-12.9M
Research and development18.2M12.9M15.4M13.2M9.54M
Selling, general and administrative9.42M6.93M7.52M6.01M3.35M24.0K
Operating income-27.6M-19.8M-22.9M-19.2M-12.9M-10.0K
Depreciation and amortization1.00M298.0K4.00K24.0K
EBITDA-21.9M-18.9M-12.9M14.0K
Interest expense149.0K4.00K0
Income before tax-26.4M-19.0M-22.3M-19.1M-12.9M-10.0K
Income tax-19.0M1.00K-298.0K-4.00K-24
Net income-26.4M-19.0M-22.3M-19.1M-12.9M-10.0K
Earnings per share, basic-1.32-1.11-1.43-1.51-3.02-0.00
Earnings per share, diluted-1.32-1.11-1.43-1.51-3.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents31.6M18.5M19.1M20.0M5.74M5.74M
Current assets31.7M18.6M19.2M20.4M5.83M5.83M
Total assets31.7M18.6M19.2M20.4M6.66M6.66M
Accounts payable6.27M2.50M2.77M2.91M1.06M10.0K
Current liabilities13.3M8.89M6.98M6.19M2.42M10.0K
Total liabilities13.3M8.89M6.98M6.19M2.42M10.0K
Shareholders' equity18.4M9.71M12.2M14.2M-11.0M-10.0K
Shares outstanding25.7M19.5M17.4M15.2M4.51M12.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-16.0M-12.2M-16.0M-13.6M-9.50M24.0K
Capital spending000000
Free cash flow-16.0M-12.2M-16.0M-13.6M-9.50M24.0K
Cash from investing000
Cash from financing29.1M11.7M15.1M27.8M15.2M15.2M
Share buybacks27.8M
Change in cash13.1M-593.0K-867.0K14.3M5.74M24.0K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveAug 31, 2026Other filingsSEC
S-3 · Registration statementAug 21, 2026Offer documentSEC
8-K · Current reportAug 21, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026ResultsSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJul 1, 2026Insider tradeSEC
8-K · Current reportJun 30, 2026Material contractSEC
424B5 · ProspectusJun 30, 2026Offer documentSEC
424B5 · ProspectusJun 29, 2026Offer documentSEC
8-K · Current reportJun 29, 2026Current reportSEC
8-K · Current reportJun 23, 2026Material contractSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 12, 2026Meeting outcomeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
DEFA14A · Additional proxy materialApr 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveFeb 23, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 18, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 18, 2026Other filingsSEC
S-3 · Registration statementFeb 13, 2026Offer documentSEC
8-K · Current reportFeb 11, 2026ResultsSEC
10-K · Annual reportFeb 11, 2026Annual reportSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
8-K · Current reportNov 4, 2025ResultsSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 31, 2025Insider tradeSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
8-K · Current reportSep 25, 2025Management or board changeSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4/A · Change in ownership, amendedMay 12, 2025Insider tradeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
8-K · Current reportMay 9, 2025Current reportSEC
424B5 · ProspectusMay 9, 2025Offer documentSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
10-K · Annual reportFeb 25, 2025Annual reportSEC
8-K · Current reportFeb 25, 2025ResultsSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
424B5 · ProspectusFeb 6, 2025Offer documentSEC
8-K · Current reportFeb 5, 2025Material contractSEC
424B5 · ProspectusFeb 4, 2025Offer documentSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
S-8 · Registration statement for employee plansJan 3, 2025Offer documentSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
4/A · Change in ownership, amendedDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 8, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 5, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2024Quarterly reportSEC
8-K · Current reportNov 5, 2024ResultsSEC
8-K · Current reportAug 29, 2024Current reportSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
8-K · Current reportJun 13, 2024Meeting outcomeSEC
4 · Change in ownershipMay 15, 2024Insider tradeSEC
4 · Change in ownershipMay 13, 2024Insider tradeSEC
4 · Change in ownershipMay 13, 2024Insider tradeSEC
4 · Change in ownershipMay 13, 2024Insider tradeSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
10-K · Annual reportMar 5, 2024Annual reportSEC
8-K · Current reportMar 5, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 28, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 6, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 31, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 31, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 30, 2024Big-stake noticeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
8-K · Current reportNov 8, 2023ResultsSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
4 · Change in ownershipOct 12, 2023Insider tradeSEC
4 · Change in ownershipOct 10, 2023Insider tradeSEC
4 · Change in ownershipOct 6, 2023Insider tradeSEC
8-K · Current reportSep 12, 2023Current reportSEC
8-K · Current reportAug 17, 2023Current reportSEC
4 · Change in ownershipAug 16, 2023Insider tradeSEC
4 · Change in ownershipAug 11, 2023Insider tradeSEC
S-8 · Registration statement for employee plansAug 9, 2023Offer documentSEC
8-K · Current reportAug 9, 2023ResultsSEC
10-Q · Quarterly reportAug 9, 2023Quarterly reportSEC
4 · Change in ownershipAug 1, 2023Insider tradeSEC
4 · Change in ownershipJul 31, 2023Insider tradeSEC
4 · Change in ownershipJul 28, 2023Insider tradeSEC
4 · Change in ownershipJul 27, 2023Insider tradeSEC
4 · Change in ownershipJul 24, 2023Insider tradeSEC
4 · Change in ownershipJul 24, 2023Insider tradeSEC
4 · Change in ownershipJul 20, 2023Insider tradeSEC
4 · Change in ownershipJul 20, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 13, 2023Insider tradeSEC
4 · Change in ownershipJul 12, 2023Insider tradeSEC
4 · Change in ownershipJul 10, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 6, 2023Insider tradeSEC
8-K · Current reportJul 3, 2023ResultsSEC
4 · Change in ownershipJun 27, 2023Insider tradeSEC
4 · Change in ownershipJun 27, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 23, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
8-K · Current reportJun 16, 2023Management or board changeSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
4 · Change in ownershipJun 8, 2023Insider tradeSEC
4 · Change in ownershipJun 1, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 18, 2023Insider tradeSEC
8-K · Current reportMay 15, 2023ResultsSEC
10-Q · Quarterly reportMay 10, 2023Quarterly reportSEC
8-K · Current reportMay 10, 2023ResultsSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
SC 13G · Big-stake noticeApr 3, 2023Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMar 30, 2023Other filingsSEC
4 · Change in ownershipMar 28, 2023Insider tradeSEC
CORRESP · Letter to the SECMar 27, 2023Other filingsSEC
10-K/A · Annual report, amendedMar 27, 2023Annual reportSEC
4 · Change in ownershipMar 27, 2023Insider tradeSEC
4 · Change in ownershipMar 23, 2023Insider tradeSEC
4 · Change in ownershipMar 22, 2023Insider tradeSEC
UPLOAD · Letter from the SECMar 21, 2023Other filingsSEC
S-3 · Registration statementMar 17, 2023Offer documentSEC
4 · Change in ownershipMar 17, 2023Insider tradeSEC
4 · Change in ownershipMar 16, 2023Insider tradeSEC
10-K · Annual reportMar 8, 2023Annual reportSEC
8-K · Current reportMar 7, 2023ResultsSEC
SC 13G · Big-stake noticeFeb 13, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 13, 2023Big-stake noticeSEC
4 · Change in ownershipJan 13, 2023Insider tradeSEC
4 · Change in ownershipJan 13, 2023Insider tradeSEC
4 · Change in ownershipJan 13, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 9, 2023Big-stake noticeSEC
4 · Change in ownershipDec 22, 2022Insider tradeSEC
4 · Change in ownershipNov 30, 2022Insider tradeSEC
4 · Change in ownershipNov 29, 2022Insider tradeSEC
4 · Change in ownershipNov 21, 2022Insider tradeSEC
4 · Change in ownershipNov 18, 2022Insider tradeSEC
4 · Change in ownershipNov 16, 2022Insider tradeSEC
8-K · Current reportNov 8, 2022ResultsSEC
10-Q · Quarterly reportNov 8, 2022Quarterly reportSEC
4 · Change in ownershipOct 3, 2022Insider tradeSEC
4 · Change in ownershipSep 27, 2022Insider tradeSEC
4 · Change in ownershipSep 27, 2022Insider tradeSEC
4 · Change in ownershipSep 6, 2022Insider tradeSEC
4 · Change in ownershipSep 6, 2022Insider tradeSEC
4 · Change in ownershipSep 2, 2022Insider tradeSEC
4 · Change in ownershipAug 30, 2022Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 25, 2022Other filingsSEC
CORRESP · Letter to the SECAug 23, 2022Other filingsSEC
4 · Change in ownershipAug 22, 2022Insider tradeSEC
UPLOAD · Letter from the SECAug 19, 2022Other filingsSEC
4 · Change in ownershipAug 16, 2022Insider tradeSEC
S-1 · Registration statementAug 15, 2022Offer documentSEC
DAug 10, 2022Other filingsSEC
10-Q · Quarterly reportAug 10, 2022Quarterly reportSEC
8-K · Current reportAug 5, 2022ResultsSEC
8-K · Current reportJul 29, 2022Material contractSEC
4 · Change in ownershipJun 30, 2022Insider tradeSEC

This page holds 200 of 275 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Nuvectis Pharma, Inc.’s releases · as of Oct 30, 2026

Common shares
34,388,908
Fully diluted
34,388,908

Fully diluted

LineSharesAs of
Common shares34,388,908Oct 30, 2026

Share count over time

CountShares
Oct 30, 202634,388,908

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Soleus Capital Management, L.P.1.71M5.0%US$36.1MSep 30, 2026
Tang Capital Management LLC1.58M4.6%US$33.3MSep 30, 2026
Braidwell LP1.57M4.6%US$33.2MSep 30, 2026
BlackRock1.31M3.8%US$27.6MSep 30, 2026
Vanguard1.21M3.5%US$25.6MSep 30, 2026
Iridian Asset Management LLC793K2.3%US$16.8MSep 30, 2026
Geode Capital503K1.5%US$10.6MSep 30, 2026
Parkman Healthcare Partners LLC425K1.2%US$8.98MSep 30, 2026
Baldwin Wealth Partners LLC382K1.1%US$8.07MSep 30, 2026
State Street369K1.1%US$7.79MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Occam Crest Management LP357K1.0%US$7.54MSep 30, 2026
Sphera Funds Management LTD.323K0.94%US$6.83MSep 30, 2026
Schonfeld Strategic Advisors LLC260K0.76%US$5.5MSep 30, 2026
Perceptive Advisors LLC240K0.70%US$5.07MSep 30, 2026
Northern Trust171K0.50%US$3.61MSep 30, 2026
Susquehanna145K0.42%US$3.06MSep 30, 2026
UBS126K0.37%US$2.66MSep 30, 2026
Fidelity112K0.33%US$2.37MSep 30, 2026
Avidity Partners Management LP100K0.29%US$2.12MSep 30, 2026
Invesco89,3020.26%US$1.89MSep 30, 2026
Oppenheimer & Co Inc86,2910.25%US$1.82MSep 30, 2026
Schwab66,3690.19%US$1.4MSep 30, 2026
Forbes J M & Co LLP59,0000.17%US$1.25MSep 30, 2026
Wellington58,7300.17%US$1.24MSep 30, 2026
Nuveen51,0480.15%US$1.08MSep 30, 2026
Informed Momentum Co LLC48,3630.14%US$1.02MSep 30, 2026
Point72 Asset Management, L.P.46,2290.13%US$976KSep 30, 2026
BNY44,5980.13%US$942KSep 30, 2026
Citadel43,9400.13%US$928KSep 30, 2026
Strs Ohio42,5000.12%US$898KSep 30, 2026
Sei Investments Co36,0590.10%US$762KSep 30, 2026
Goldman Sachs34,3720.10%US$726KSep 30, 2026
AQR Capital Management LLC32,1460.09%US$679KSep 30, 2026
Acadian Asset Management LLC31,4380.09%US$661KSep 30, 2026
Quadrature Capital Ltd24,7010.07%US$522KSep 30, 2026
Bank of America22,9790.07%US$485KSep 30, 2026
State Of Wisconsin Investment Board20,8560.06%US$440KSep 30, 2026
Austin Wealth Management, LLC20,1250.06%US$405KSep 30, 2026
Rhumbline Advisers19,5320.06%US$413KSep 30, 2026
Squarepoint Ops LLC19,0950.06%US$403KSep 30, 2026
DWS17,9480.05%US$379KSep 30, 2026
T. Rowe Price17,2390.05%US$365KSep 30, 2026
Morgan Stanley14,9470.04%US$316KSep 30, 2026
Simplex Trading, LLC14,9320.04%US$315KSep 30, 2026
CPP Investments14,0000.04%US$296KSep 30, 2026
Avalon Trust Co14,0000.04%US$296KSep 30, 2026
Creative Planning13,9850.04%US$295KSep 30, 2026
JPMorgan12,8810.04%US$264KSep 30, 2026
MetLife Investment Management, LLC11,5200.03%US$243KSep 30, 2026
Captrust Financial Advisors10,5070.03%US$222KSep 30, 2026

This page holds 50 of 91 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund482K1.4%US$8.87MJun 30, 2026
iShares Russell 2000 ETF431K1.3%US$7.92MJun 30, 2026
Vanguard Extended Market Index Fund199K0.58%US$3.65MJun 30, 2026
Fidelity Small Cap Index Fund187K0.54%US$4.03MJul 31, 2026
iShares Russell 2000 Growth ETF158K0.46%US$2.91MJun 30, 2026
Fidelity Extended Market Index Fund90,4940.26%US$882KMay 31, 2026
Vanguard Russell 2000 Index Fund79,7380.23%US$777KMay 31, 2026
iShares Micro-Cap ETF56,5770.16%US$1.04MJun 30, 2026
Schwab Small-Cap Index Fund41,5330.12%US$894KJul 31, 2026
Master Small Cap Index Series33,4440.10%US$615KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Series Total Market Index Fund31,3990.09%US$306KMay 31, 2026
Fidelity Total Market Index Fund28,0650.08%US$274KMay 31, 2026
Nuveen Small Cap Blend Index Fund22,6740.07%US$488KJul 31, 2026
Nuveen Equity Index Fund18,1490.05%US$391KJul 31, 2026
EQ/2000 Managed Volatility Portfolio18,1020.05%US$333KJun 30, 2026
Fidelity Nasdaq Composite Index Fund16,1350.05%US$157KMay 31, 2026
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF16,0850.05%US$157KMay 31, 2026
Fidelity Small Cap Growth Index Fund16,0180.05%US$295KJun 30, 2026
Schwab Total Stock Market Index Fund15,6000.05%US$336KJul 31, 2026
Vanguard Russell 2000 Growth Index Fund14,4810.04%US$141KMay 31, 2026
LVIP State Street Small-Cap Index Fund12,3000.04%US$226KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund9,3540.03%US$172KJun 30, 2026
Small Cap Index Fund8,8200.03%US$162KJun 30, 2026
Global X Russell 2000 ETF8,1540.02%US$175KJul 31, 2026
Vanguard Balanced Index Fund8,0540.02%US$148KJun 30, 2026
ATM Small Cap Managed Volatility Portfolio5,5940.02%US$103KJun 30, 2026
Small Cap Index Fund5,2340.02%US$51,032May 31, 2026
MetLife Russell 2000 Index Portfolio5,1650.02%US$94,984Jun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio5,0000.01%US$91,950Jun 30, 2026
Small-Cap Index Portfolio4,7010.01%US$86,451Jun 30, 2026
1290 VT Micro Cap Portfolio3,7840.01%US$69,588Jun 30, 2026
Small Cap Index Trust3,5150.01%US$64,641Jun 30, 2026
NVIT Small Cap Index Fund3,4710.01%US$63,832Jun 30, 2026
Bridge Builder Small/Mid Cap Growth Fund3,098<0.01%US$56,972Jun 30, 2026
EQ/AB Small Cap Growth Portfolio2,850<0.01%US$52,412Jun 30, 2026
EQ/Small Company Index Portfolio2,850<0.01%US$52,412Jun 30, 2026
DWS Small Cap Index VIP2,686<0.01%US$49,396Jun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio2,541<0.01%US$46,729Jun 30, 2026
iShares Total U.S. Stock Market Index Fund2,394<0.01%US$51,519Jul 31, 2026
T. Rowe Price Small-Cap Index Fund2,344<0.01%US$43,106Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund2,341<0.01%US$50,378Jul 31, 2026
BlackRock Small Cap Index V.I. Fund2,245<0.01%US$41,286Jun 30, 2026
Voya RussellTM Small Cap Index Portfolio2,190<0.01%US$40,274Jun 30, 2026
SA Small Cap Index Portfolio2,002<0.01%US$43,083Jul 31, 2026
Siit Extended Market Index Fund1,900<0.01%US$18,525May 31, 2026
Victory Extended Market Index Fund1,789<0.01%US$38,499Jul 31, 2026
Vanguard Russell 3000 Index Fund1,623<0.01%US$15,824May 31, 2026
Nationwide Small Cap Index Fund1,565<0.01%US$33,679Jul 31, 2026
PD Small-Cap Growth Index Portfolio1,519<0.01%US$27,934Jun 30, 2026
SmallCap Growth Fund I1,475<0.01%US$31,742Jul 31, 2026

This page holds 50 of 74 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Bentsur Ron
Director, Officer: Chairman & CEO, 10% owner
Buy12,500USD 20.00US$250KJun 30, 2026
Mosseri Marlio Charles
10% owner
Buy50,000USD 18.32US$916KJun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Soleus Capital Management, L.P.5.10%1.65MAug 4, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Kenneth Hoberman
Other companies: TG Therapeutics, Inc. (Chief Operating Officer and Corporate Secretary · Since at least Jun 26, 2018); Stemline Therapeutics Inc (Chief Operating Officer · Dec 15, 2017 – Jun 10, 2020 · Past)
Director · Since at least Feb 8, 2022
Ron Bentsur
Other companies: Beyond Air, Inc. (Director · Jul 27, 2020 – Nov 22, 2024 · Past); Stemline Therapeutics Inc (Director · Jun 25, 2019 – Jun 10, 2020 · Past)
Chairman & CEO, Director · Since at least Feb 4, 2022
James F Oliviero III
Other companies: Checkpoint Therapeutics Inc (CEO, President and Director, Director · Since at least Apr 2, 2025)
Director · Since at least Jun 12, 2025
Uri Ben-or
Other companies: Scinai Immunotherapeutics Ltd. (Director · Since at least Jan 1, 2023)
Int. Principal Financial Off. · Feb 8, 2022 – Feb 8, 2022 · Past
Enrique PoradosuExecutive Vice President, Chief Scientific and Business Officer · Since at least Jan 3, 2024
James F. OlivieroDirector · Since at least Jun 12, 2026
Juan SanchezDirector · Since at least Sep 25, 2025
Ken HobermanDirector · Since at least Jun 12, 2026
Matthew L. KaplanDirector · Since at least Jun 12, 2026
Ron BentsurChairman, Chief Executive Officer and President · Since at least Jul 1, 2026
All 11 people
PersonSeat
Shay ShemeshChief Dev. & Ops. Officer · Since at least Jan 6, 2026

Open People

Log in to ask 6ix AI your own questions about Nuvectis Pharma, Inc.